NUVL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Nuvalent submitted NDA to FDA for Neladalkib in ALK-positive lung cancerApr 7, 2026
- Nuvalent announces FDA acceptance of New Drug Application for Zidesamtinib for advanced ROS1-positive NSCLC patientsNov 20, 2025
- Nuvalent announced positive topline pivotal data from ALKOVE-1 trial of Neladalkib for TKI pre-treated advanced ALK-positive NSCLC patientsNov 17, 2025
- Nuvalent presents pivotal data from ARROS-1 clinical trial of Zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC at WCLC 2025Sep 8, 2025
- Nuvalent to present pivotal data from ARROS-1 clinical trial of Zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC at WCLC 2025 Presidential SymposiumAug 14, 2025